**Article**

**Phytochemistry, Food Application, and Therapeutic Potential of the Medicinal Plant (*Withania coagulans*): A Review**

Muhammad Issa Khan ¹, Maria Maqsood ¹, Raakia Anam Saeed ¹, Amna Alam ¹, Amna Sahar ¹,², Marek Kieliszek ³, Antoni Miecznikowski ⁴, Hafiz Shehzad Muzammil ¹ and Rana Muhammad Aadil ¹,⁎

¹ National Institute of Food Science and Technology, University of Agriculture, Faisalabad 38000, Pakistan; mariamaqsood79@gmail.com (M.M.); raakia.anam@gmail.com (R.A.S.); annahnd17@gmail.com (A.A.); amnasahar@uaf.edu.pk (A.S.); shehzad.muzammil@uaf.edu.pk (H.S.M.)

² Department of Food Engineering, University of Agriculture, Faisalabad 38000, Pakistan

³ Department of Food Biotechnology and Microbiology, Institute of Food Science, Warsaw University of Life Sciences—SGGW, Nowoursynowska 159 C, 02-776 Warsaw, Poland; marek.kieliszek@sggw.edu.pl

⁴ Department of Fermentation Technology, Prof. Waclaw Dabrowski Institute of Agricultural and Food Biotechnology—State Research Institute, Rakowiecka 36, 02-532 Warsaw, Poland; antoni.miecznikowski@ibprs.pl

⁎ Correspondence: drkhan@uaf.edu.pk (M.I.K.); muhammad.aadil@uaf.edu.pk (R.M.A.)

**Abstract:** Herbal plants have been utilized to treat and cure various health-related problems since ancient times. The use of Ayurvedic medicine is very significant because of its least reported side effects and host of advantages. *Withania coagulans* (Family; Solanaceae), a valuable medicinal plant, has been used to cure abnormal cell growth, wasting disorders, neural as well as physical problems, diabetes mellitus, insomnia, acute and chronic hepatic ailments. This review provides critical insight regarding the phytochemistry, biological activities, and pharmacognostic properties of *W. coagulans*. It has been known to possess diuretic, anti-inflammatory, anti-bacterial, anti-fungal, cardio-protective, hepato-protective, hypoglycemic, anti-oxidative, and anti-mutagenic properties owing to the existence of withanolides, an active compound present in it. Apart from withanolides, *W. coagulans* also contains many phytochemicals such as flavonoids, tannins, and β-sterols. Several studies indicate that various parts of *W. coagulans* and their active constituents have numerous pharmacological and therapeutic properties and thus can be considered as a new drug therapy against multiple diseases.

**Keywords:** Ayurvedic properties; diuretic; phytochemistry; pharmacognostic properties

---

**1. Introduction**

Plants are potential sources of medicinal compounds and have been used as ancient healing systems since antiquity. Some medicinal plants are enriched with diverse bioactive constituents. These bioactive constituents have been reported as beneficial to prevent and treat various disorders for maintaining a healthy life. One of the most important medicinal plants of genus *Withania* is *Withania coagulans* in the Ayurvedic medicinal system owing to its effective nutraceutical as well as pharmaceutical attributes. It is grown in various regions of the world such as in the Mediterranean region and from North Africa to South Asia [1]. Among twenty-three identified species of genus *Withania*, only two (*W. coagulans* and *W. somnifera*) have economic significance [2]. This plant is widely used to coagulate milk due to the presence of an enzyme in its berries, which is commonly known as an Indian cheesemaker [3]. Figure 1 depicts the leaves, stems, and fruit of the *W. coagulans* plant. The fruit, roots, and leaves have various therapeutic effects. The main constituents in berries include essential oils, esterases, amino acids, and alkaloids [4]. The healing properties of the plant are attributed to steroid derivative compounds “Withanolides”. There are several withanolides such as coagulin F, coagulanolide, withacoagulin, and
Molecules 2021, 26, 6881
2 of 15
coualgin G present in the whole plant [3]. The ripe fruit of the plant is sweet and used for wound healing, asthma and dyspepsia, and as a sedative. In many countries, dry fruit is also used as a traditional treatment for diabetes [5] and as an antibacterial [6], antimicrobial [7], hepatoprotective [8], hypolipidemic [9], antioxidant [10], anti-tumor [11], antidepressant [12], immunosuppressive [13], and anti-inflammatory agent [14]. Seeds are useful for reducing inflammation, as a diuretic, and also in curing ophthalmia, while flower buds showed anthelmintic activity [15–17]. Twigs of the plant are used for cleaning teeth, as toothache and blood purifier agents in South Asian regions [3]. By considering the growing utilization of medicinal plants and their application in various indigenous health systems, this review is intended to provide comprehensive knowledge on phytochemistry, food uses, and the therapeutic potential of W. coagulans.

Figure 1. W. coagulans plant. (A): Leaves, (B): Fruits, (C): Stems.

2. Nutritional Profile

W. coagulans is a renowned herb due to its ethnopharmacological properties. It has been utilized as a herbal remedy and is widely distributed in Iran, Pakistan, Afghanistan, and East India. W. coagulans is a good source of macro and micronutrients. The mineral composition of W. coagulans is summarized in Table 1. It contains a small fraction of moisture, protein, fat, and fiber and is also a good source of carbohydrates. Studies also indicate a higher amount of magnesium (greater than Alhagi maurorum, Berberis lyceum, and Tecomella undulate), calcium (greater than Dature alba, A. maurorum, Chenopodium album, B. lyceum, T. undulate), potassium (greater than B. lyceum and T. undulate), and iron (greater than D. alba, B. lyceum, and T. undulate) in W. coagulans [4]. Roots are composed of ash (1.92%), carbohydrates (75.71%), lipids (5.5%), protein (2.95%), and fiber (5.76%). Leaves are composed of ash (3.26%), carbohydrates (65.31%), lipids (5%), protein (2.95%), and fiber (11.76%). Moreover, fruit contains ash (4.21%), carbohydrates (60.14%), lipids (5%), and protein (4.65%) [18].

The berries of the W. coagulans are composed of milk coagulating enzymes, two esterase, free amino acids, and essential oil. Proline, tyrosine, valine, hydroxyproline, glycine, cysteine, asparagine, glutamic, and aspartic acids are the main amino acids that are present in the plant. Major fatty acids include arachidonic acid, stearic acid, palmitic acid, linoleic and oleic acids [3]. Furthermore, n-octatriacont-17-enio acid, geranil-10-0-yl dihydromarnooate (aromatic ester), and geranil-8-oic acid-10-0-yl salicyloyloxy-2-O-β-D-glucofuranosyl(6”→1”)-O-β-D-glucofuranosyl-6”-n-octade-9””,11””,””-dienoate(monoterpenic benzyl glucoside) in consort with two already identified fatty acids named as n-dotriacont-21-enio acid and n-tetraatriacontonoic acid were characterized in berries [19]. Similarly, research also detected twenty constituents in the essential oil of the W. coagulans fruit including sesquiterpenes (54%)}
and esters (21.50%) as dominant compounds followed by the presence of fatty acids (5.5%) such as nonanoic acid, hexanoic acid, methyl ester of hexadecanoic acid, methyl ester of nonadecanoic acid, methyl esters of 8,11-octadecadienoic acid, methyl ester of 9-octadecenoic acid, and ethyl ester of linoleic acid, alkanes (9.11%), and the aldehydes (0.32%) in smaller percentage [20]. The un-saponifiable matter of the plant seed is composed of triacontane as well as β-sitosterol and dihydrostigmasterol [21]. In addition, it was reported that seeds are composed of approximately 12–14% of oil. The presence of free sugar (17.8%) in the form of D-galactose and D-arabinose (1:1) in a de-fatted meal of the W. coagulans seeds was also elucidated with maltose present in trace amounts [22]. Higher percentages of β-sitosterol, as well as linoleic acid, were also found and reported for the hypo-cholesterolemic effect of corn oil in combination with W. coagulans [15,23].

Table 1. Mineral composition of W. coagulans [4].

| Minerals (mg/kg) | Macro-Minerals | Micro-Minerals |
|-----------------|---------------|---------------|
| Calcium         | 9260          | Iron 98.8     |
| Magnesium       | 35,280        | Copper 2.2    |
| Potassium       | 2450          | Zinc 40.2     |
| Sodium          | 125           | Chromium 0.6  |
| Micro-Minerals  |               | Cadmium 1.4   |
|                 |               | Lead 1.9      |
|                 |               | Nickel 1.8    |

3. Phytochemistry

Withania species have been studied extensively by several researchers that subsequently led to the identification, characterization, and isolation of bioactive compounds in different parts of a plant. It includes several steroidal lactones, tannins, flavonoids, and alkaloids [24–26]. Ten new phytoconstituents were identified from air-dried W. coagulans fruit extracted with methanol and their structures were based on their chemical and spectral data [27]. Various constituents of W. coagulans were estimated in three different extracts namely, methanolic, hydroalcoholic, and chloroform. It was reported that total phenolic content (55.9 mg/g), total tannins (76.6 mg/g), total flavonoids (0.88 mg/g), and total flavanol (0.25 mg/g) were higher in the methanolic extract as compared to hydroalcoholic and chloroformic [28].

In a study conducted in Iran, the presence of flavonoids (5.70–6.50%), anthocyanins (4.51–9.51 µmol/g), and total phenolics (14.91–23.7 µg gallic acid equivalent (GAE)/mg D.W) were confirmed in W. coagulans [29]. The leaves of W. coagulans demonstrated the levels of total phenolics (58.21 mg GEA/g) and flavonoids (47 mg rutin equivalent (RE)/g), respectively [30]. The important chemical constituents of this medicinal plant are the withanolides, a series of polyhydroxy steroidal lactones, mainly present in the leaves as well as roots. They are composed of C-28 steroidal lactones based on the ergostane structure and the six or five-membered lactone ring is formed by oxidation of C-22 and C-26 [25]. Their concentrations vary from 0.001% to 0.5% of the dry weight [26,31–33]. Two major groups include withanolides containing the modified carbocyclic structure and withanolides containing the unmodified skeleton (including the regular β-oriented side chains and the unusual α-oriented side chains). They are classified into seven groups based on being derivatives of ergostane and include 5β,6β–epoxides; 6α,7α–epoxides; 5-enes; intermediate compounds; 5α,6α–epoxides; 6β,7β–epoxides, and phenolic withanolides [31,34].
So far, several withanolides, alkaloids, and sitoindosides (withanolide with glucose molecule at carbon 27) have been reported and isolated from *Withania* species [24,26,35–46]. One of the most salient features that withanolide-producing plants possess is to host an oxygen function in almost all positions of side chains or carbocyclic skeletons. Novel structural variants arise by modifications in either the side chain or in the carbocyclic skeleton [15].

### 4. Novel Isolated Compounds of *W. coagulans*

Several compounds have been identified in different parts of *W. coagulans* including certain coagulans, coagulanolide, and coagulins. Choudhary et al., [40] identified 17β-hydroxywithanolide K: [(20S,22R)14α,17β,20β-trihydroxy-1-oxo-witha-2,5,24-trienolide] and 17β,20β-dihydroxy-1-oxo-witha-2,5,24-trienolide in whole plant. Similarly, Shahwar [47] found withahejarin, withasomniferine-A along with coagulin A. Furthermore, identification and isolation of thirteen coagulins (Coagulin F, G, H, I, J, K, L, M, N, O, P, Q, and R) from the whole plant was reported [41,48,49]. *W. coagulans* also contains coagulin U along with other metabolites such as methyl-4–benzoate and phytosterols (β-sitosterol, β-sitosterol glycoside). Similarly, (22R)-14,20-epoxy-17β-hydroxy-1-oxowitha-3,5,24-trienolide and (22R)-14,20-epoxy-17β-hydroxy-1-oxowitha-3,5,25-trienolide which are also important constituents of it [50]. Moreover, 17β,27-dihydroxy-14,20-epoxy-1-oxo-22R-witha-3,5,24-trienolide and 17β-hydroxy-14α,20α-epoxy-1-oxo-(22R)-witha-3,5,24-trienolide were discovered [41]. Coagulin S was also isolated, and its structure was elucidated by using spectroscopic techniques [44]. Coagulansin B and coagulanolide are also amongst the metabolites of *W. coagulans* [51,52]. Withacoagulin J was identified as well as isolated along with already known withanolide H [53]. Withanolide named as (20R,22R)-14α,17,20β,27-trihydroxy-1-oxowitha-5,24-dienolide-27β-(O-β-D-glucopyranoside) was also discovered latterly [53,54]. Furthermore, withacogulanoside-B along with five known withanolides was isolated [55]. The compounds present in different plant parts are given in Table 2. Furthermore, the structures of some withanolides are presented in Figure 2.

| Molecules | Part of Plant | References |
|-----------|---------------|------------|
| Withaferin A | Root | [35] |
| (20R,22R)-6α,7α-epoxy-5α,20-dihydroxy-1-oxo-witha-2,24-dienolide | Root | [39] |
| Withacoagin: (20R,22R)-5α,20-dihydroxy-1-oxo-witha-2,6,24-trienolide | Aerial parts (leaves and stem), whole plant | [48,52] |
| Coagulin B, Coagulin C, Coagulin D, Coagulin E, Coagulin R | Aerial parts (leaves and stem) | [50] |
| Amyrin | Aerial parts (leaves and stem) | [56] |
| Withacoagulin A: | Aerial parts (leaves and stem) | [56] |
| (1/2(20R,22R)-17β,20β-dihydroxy-1-oxo-witha-3,5,14,24-tetraenolide) | Withacoagulin B: | |
| (1/2(20R,22R)-20β,27-dihydroxy-1-oxo-witha-3,5,14,24-tetraenolide) | Withacoagulin C: | |
| (1/2(20R,22R)-14α,15α,17β,20β-tetrahydroxy-1-oxo-witha-3,5,24-trienolide) | Withacoagulin D: | |
| (1/2(20R,22R)-14α,17β,20β-tetrahydroxy-1-oxo-witha-3,5,24-trienolide) | Withacoagulin E: | |
| (1/2(20R,22R)-14β,20β-dihydroxy-1-oxo-witha-2,5,24-trienolide) | Withacoagulin F: | |
| (1/2(20R,22R)-14β,20β-dihydroxy-1-oxo-witha-3,5,24-trienolide) | Withanolide L | |
| (22R)-14α,15α,17β,20β-tetrahydroxy-1-oxo-witha-2,5,24-trien-26,22-olide) | |
Table 2. Cont.

| Molecules                                                                 | Part of Plant                  | References |
|---------------------------------------------------------------------------|-------------------------------|------------|
| Coagulansin A: (14α,17S,20S,22R)-14,17,20,27-tetrahydroxy-1-oxowitha-2,5,24-trienolide) | Whole plant, aerial parts     | [52,57]    |
| Coagulansin B: (3β,14α,20S,22R)-3,14,20-trihydroxy-1-oxowitha-5-enolide) |                               |            |
| Withanolide P: (1/α(17α,22R)-14,17,22-trihydroxy-1-oxoergosta-2,5,24-trien-26-oic acid δ-lactone)(14R,15R,17S,20S,22R)-14,15,17,20-tetrahydroxy-1-oxowitha-2,5,24-trienolide) | Aerial part (leaves)          | [36]       |
| (14R,15R,17S,20S,22R)-14,15,17,20-tetrahydroxy-1-oxowitha-3,5,24-trienolide) |                               | [37]       |
| (14S,20α(R)-dihydroxy-6α,7α-epoxy-1-oxo-(5α)witha-2,24-dienolide)         | Fruit                         | [38]       |
| (3β-hydroxy-2,3-dihydrowithanolide F) Withanolide D |                               |            |
| (3β-hydroxy-2,3-dihydrowithanolide F) | Fruit                         | [39]       |
| (3β,14α,20αF,27-tetrahydroxy-1-oxo-20R,22R-witha-5,24-dienolide) Withanolide H: (14α,20αF,27-tetrahydroxy-1-oxo-20R,22R-witha-5,24-dienolide) | Fruit                         | [58]       |
| Ajugin E                                                                     | Fruit                         | [49]       |
| Ajugin A                                                                     | Fruit                         | [50]       |
| Withacoagulin: (20β,27-dihydroxy-1-oxo-(22R)-witha-2,5,24-tetraenolide)     | Fruit                         | [43]       |
| (20β-hydroxy-1-oxo-(22R)-witha-2,5,24-tetraenolide)                         |                               |            |
| Coagulanolide (17S,20S,22R)-14α,15α,17β,20β-tetrahydroxy-1-oxowitha-2,5,24-trienolide) | Fruit                         | [51]       |
| (20R,22R)-14,20α,27-trihydroxy-1-oxowitha-3,5,24-trienolide                | Fruit                         | [56]       |

Figure 2. Structure of Withanolides of W. Coagulans.

5. Application in the Food Industry

Berries of W. coagulans are well known for their milk coagulating potential. Keeping this property in view, the milk coagulating activity of protease from the plant was assessed. A temperature of 70 °C and pH 4 were found to be optimal for enzymatic activity. However, 60 °C was a stable temperature for the activity of the enzyme; SDS-PAGE showed a 66 kDa band [59]. Furthermore, the fruit extract of W. coagulans was utilized to assess the milk coagulating potential which demonstrated the highest impact at pH of 4 and temperature of 65 °C. Additionally, the time for rennet congealing of the extract was observed to be in direct relation with concentrations of NaCl or inversely with enzyme concentrations (protease inhibitors). Moreover, pepstatin-A (aspartic-protease inhibitor) completely inhibited the enzymatic potential of the berry extract [60].
An enzyme aspartic protease was isolated by using fractional ammonium-sulfate precipitation and cation-exchange chromatography from *W. coagulans* fruit. Furthermore, SDS-PAGE revealed the existence of a monomeric protein with a molecular weight of 31 kDa. The proteolytic activity of the protease enzyme was assessed using casein revealed $K_m$ (1.29 mg/mL) and $V_{max}$ (0.035 µmol Tyr/min) values for the protease enzyme. Skim milk was utilized to assess the milk coagulating potential of *W. coagulans* crude fruit extract. Consequently, mass spectrometry and inhibition assays revealed that aspartic protease is the only enzyme involved in milk coagulation. Additionally, the increasing salts concentrations (NaCl, CaCl$_2$) gradually reduced the enzyme activity. Thus, it was concluded that this enzyme may be apt to produce the low salt cheese [61]. The protease was extracted from the berries of the plant and used for the production of white cheese. It was documented that cheese from *W. coagulans* was more acidic than cheeses prepared from other rennet sources [62].

Buffalo milk mozzarella cheese was developed by using fruits of *W. coagulans* as milk coagulants. Thus, an aqueous fraction of *W. coagulans* may be a suitable option for cheese production [63]. Buffalo milk cheese was developed by using an extract of the fruit of *W. coagulans* and was evaluated in terms of storage conditions (5 months). The highest content of ash, fat, crude protein as well as total solids was observed in cheese prepared with lyophilized berry extract [64]. Cheese preparation was done by using alcoholic and aqueous fractions of *W. coagulans* at different levels (0.5, 1, and 1.5%) containing plant protease [65].

Furthermore, the preparation of cottage cheese from an aqueous fraction of plant showed significantly higher moisture content as well as pH, however, no difference in ash, fat, and crude protein was observed in cheese prepared from calf rennet and *W. coagulans* [66]. An acceptable quality white cheese can be developed by the utilization of 0.5% alcoholic extract of the plant. The soy milk coagulating potential of *W. coagulans* extract was assessed in tofu preparation and compared with calcium-sulfate tofu. Sensory analysis revealed no difference between both types of tofu. However, yield as well as moisture content was lower in *W. coagulans*’s tofu [67].

### 6. Application in Nanotechnology

Silver nanoparticles (AgNPs) have prodigious potential on behalf of their mechanistic role in biomedical research. Approaches involving green chemistry have gained copious attention recently in plant science for the production of nanoparticles. Keeping in view this fact, leaf extract *W. coagulans* was utilized for the development of reduced graphene oxide (RGO)/Fe$_3$O$_4$ based nanocomposite with palladium nanoparticles (Pd/RGO/Fe$_3$O$_4$) and resulted in the reduction in 4-nitrophenol in the water at ambient temperature [68]. Silver nanoparticles were developed by using *W. coagulans* leaf extract and characterization of those nanoparticles was conducted by using UV–Vis, scanning electron microscopy, energy dispersive X-ray analysis, transmission electron microscopy, X-ray powder diffraction, and Fourier transform infra-red. The cumulative result indicated the size of particles as 14 nm having a spherical face-centered cubic structure [69].

Encapsulation of the water extract was performed by developing chitosan nanoparticles coated with food-based starch to retard extract release in the stomach. The release was retarded by 2.5 times by this method, hence exerting hypoglycemic potential [70]. *W. coagulans* was utilized to develop iron oxide nanorods. Iron oxide nanorods with an average size of 16 ± 2 nm and highly crystalline nature was obtained [6]. Furthermore, Keshari [71] also used *W. coagulans* extract to develop green silver nanoparticles. Those nanoparticles were crystalline, elemental, and spherical which also showed anti-biotic potential.

### 7. Therapeutic Potential of *W. coagulans*

A number of medicinal properties are attributed to *W. coagulans* such as antifungal, anti-cytotoxic, antidiabetic, hypolipidemic, neuroprotective, anti-inflammatory, anticancerous, anthelmintic, antioxidant activity, and wound healing activity [15]. Various
pharmacological and therapeutic activities of *W. coagulans* are attributed to the various plant parts including roots, leaves, and fruits as shown in Figure 3. The anti-inflammatory mechanism of action of cogulin L isolated from *W. coagulans* is illustrated in Figure 4. Available literature indicates the therapeutic role of *W. coagulans* and its withanolides is summarized in Table 3.

**Figure 3.** Graphical representation of the therapeutic potential of *W. coagulans* in several ailments.

**Figure 4.** Anti-inflammatory potential of *W. coagulans* (IκBα: Nuclear factor of kappa light polypeptide gene, iNOS: Inducible NO synthase, NFκB: Nuclear factor of kappa light polypeptide gene, TLR4: Toll-like receptor 4, ERK1/2: Extracellular signal regulator kinase, JNK1/2: c-Jun-N-terminal kinase.
Table 3. Therapeutic potential of *W. coagulans*.

| Part of Plant | Type of Intervention | Experimental Model                          | Dosage | Outcomes                                                                 | References |
|---------------|----------------------|---------------------------------------------|--------|--------------------------------------------------------------------------|------------|
| **Cardioprotective Potential** |                      |                                             |        |                                                                          |            |
| Fruit         | Methanolic extract   | Rabbits (1–1.5 kg weight)                   | 200 and 600 mg/kg BW | Improved lipid profile, HMG-COA reductase, lipase, and antioxidant activities | [9]        |
| Fruit         | Withacoagulin and coagulin C | Female Albino rats (100–120 g) | 25 and 50 mg/kg BW | Antihypertensive impact in a dose-dependent manner | [72]       |
| Fruit         | Withacoagulin        | Male Albino rats (120–150 g)               | 25 mg/kg BW | Superoxide dismutase, catalase, creatinine phosphokinase, and lactate dehydrogenase significantly reduced | [73]       |
| **Hepatoprotective Activity** |                      |                                             |        |                                                                          |            |
| Fruit         | Methanolic and aqueous-methanolic extracts (80%) | Albino rats (170–220 g) | 800 mg/kg BW | An improvement as well as biosynthesis of liver and bile duct specific enzymes. Maintenance of the integrity of the hepatic membrane | [8]        |
| **Anti-inflammatory and Immune Modulatory Activity** |                      |                                             |        |                                                                          |            |
| Fruit         | Coagulin L           | Human murine cells, mice model (male Swiss Albino mice) | 1, 3, 10 µM (In vitro) 10, 25, and 50 mg/kg BW | Suppression of TLR4 induced immune mediators including cytokines, growth factors, nitric and superoxide led towards immune-modulatory responses. Moreover, it reduced the degradation of IκBα which in turn inhibited the expression of NF-κB by downregulating the expression of iNOS and release of pro-inflammatory cytokines | [14]       |
| Fruit         | Ethanolic extract (50%) | Broiler chicken (550 male)                  | 0, 75, and 150 mg/kg diet | The concentration of immunoglobulin G was significantly improved through improving humoral response at the dosage of 150 mg/kg diet | [13]       |
| Aerial parts  | Crude extract (methanol and chloroform in 1:1) | Sprague Dawley rats (180–220 g) | 200, 100 and 50 mg/kg BW | Anti-inflammatory impact (70.0%) | [74]       |
| Plant         | Methanolic extract (80%) | Wistar rats (150–200 g) | 250 and 500 mg/kg BW | Anti-inflammatory and antioxidant activity | [75]       |
| Fruit         | Aqueous extract      | In vitro analysis                          | - | Strong antioxidant and free radical scavenging potential | [10]       |
| **Antibacterial, Antifungal and Diuretic Activity** |                      |                                             |        |                                                                          |            |
| Roots and leaves | Chloroform, ethyl acetate, and aqueous extract | Bacterial strains (Gram-positive and Gram-negative) | 0.5, 1, 1.5, and 2 mg/mL | Chloroform leaves and ethyl acetate stem extracts at a dose of 2 mg/mL had significant inhibition activity against bacterial pathogens as compared to aqueous extract | [76]       |
| Fruit         | Methanolic extract   | Klebsiella pneumonia, Escherichia coli, Salmonella paratyphi, Staphylococcus aureus, Bacillus subtilis, and Micrococcus luteus | 20 µg/mL | The highest inhibition by the methanolic extract was reported against *Bacillus subtilis* at 12 mm | [7]        |
| Fruit         | Methanolic extract   | Male Charles Foster Albino rats (150–200 g) | 400 mg/kg BW | The nephron-protective role was illustrated by the reduction in levels of free radical, renal function test, and protection from DNA damage | [77]       |
| Leaves        | Silver nanoparticles (leaf extract) | Bacterial strains (Gram-positive and Gram-negative) | 5, 10, 15, and 20 µg/mL | It curbed the growth of both gram-positive and negative bacteria | [69]       |
Table 3. Cont.

| Part of Plant | Type of Intervention | Experimental Model | Dosage | Outcomes | References |
|---------------|----------------------|--------------------|--------|----------|------------|
| Fruits        | Silver nanoparticles (fruit extract) | *Enterococcus faecalis, Staphylococcus aureus, Escherichia coli, Proteus vulgaris, Salmonella typhi, and Vibrio cholera* | 50 µg/mL | Phenolic constituents present in the *W. coagulans* can reduce silver nitrate into the silver nanoparticles. Moreover, bactericidal and bacteriostatic activity was elucidated | [71] |
| Fruit         | Iron oxide nanorods (biological and chemical) | *Pseudomonas aeruginosa and Staphylococcus aureus* | 5, 10, and 20 µg/mL | The study indicated that biological nanorods are more effective (30% higher activity) than chemically prepared nanorods. *W. coagulans* nanoparticles showed significant inhibitory potential against *P. aeruginosa* and *S. aureus* that indicates these nanoparticles are more effective than chemically prepared nanoparticles | [6] |
| Fruit         | Aqueous extract | In vitro (silver carp fillet) | 0.5% extract, 1% extract, 1% chitosan, 1% chitosan with 0.5% extract and 1% chitosan with 1% extract | Chitosan coating of extract demonstrated debility in levels of total bacterial counts and psychrophilic total bacterial counts as well as enhanced shelf life of fish fillets | [78] |
| Whole plant   | n-butanol and chloroform extract | In vitro and in silico | Ajugin E (66.7 ± 3.6 µM), withaperuvin C (407 ± 4.5 µM), withanolide J (683 ± 0.94 µM) | Withacogulanoside-B from *n*-butanol fraction and withaperuvin C as well as 27-hydroxywithanolide I with another 3 known withanolides (chloroform fraction) were identified. Among these, ajugin E showed higher α-glucosidase inhibition potential | [55] |
| Fruit         | Ethanolic extract | Wistar rats and in vitro | 400 mg/kg BW | *W. coagulans* suppressed the DPP-4 levels (63.2%) in an in vitro model at 14 µg/mL. Furthermore, restoration of pancreatic-endocrinal tissues was observed | [5] |
| Whole plant   | Aqueous extract | Sprague Dawley rats | 100 mg/kg BW | *W. coagulans* showed a promising impact on postprandial insulin level and amended the architecture of beta cells of the pancreas | [79] |
| Whole plant   | Aqueous extract | Male Sprague Dawley rats (200–300 g) | 1000 mg/kg BW | *W. coagulans* improved expression of glucagon-like peptide 1 which in turn reduced fasting as well as postprandial glucose levels | [80] |
| Fruit         | Aqueous extract | In vitro (mice pancreatic β-cells) In vivo (Male ICR mice; 28–36 g) | In vitro (1, 2, 5, 10, and 25 µM) In vivo (50 mg/kg BW) | Secretions of insulin were promoted 2-fold in cells treated with the extract. Furthermore, in vivo testing corroborated to suppress the levels of blood glucose by 60% | [70] |
| Fruit         | Aqueous extract | In vitro | 0–100 µg/mL | Chromatographic analysis revealed the presence of 17β-hydroxywithanolide K, withanolide F, and coagulin C in fruit fraction that was further illustrated cytotoxic potential against HepG2 cells. Both EAF and WF promoted insulin secretions and inhibition of glucose absorption | [81] |
Table 3. Cont.

| Part of Plant | Type of Intervention | Experimental Model | Dosage | Outcomes | References |
|---------------|---------------------|--------------------|--------|----------|------------|
| Bud           | Chloroform extract  | In vitro (L6 rat skeletal muscle cells) | 3.906, 7.8125, 15.625, 31.25, 62.5, 125, 250 and 500 µg/mL | *W. coagulans* bud illustrated significant uptake of glucose via GLUT-4 and activity of PPAR gamma that resulted in enhanced glucose dumping and insulin sensitivity in skeletal muscles | [82] |
| Whole plant   | Hydro-methanolic extract | Forty male Wistar rats (200–250 g) | 1000 mg/kg BW | *W. coagulans* extract treatment induced cell apoptosis in the prostate and the expression of cyclooxygenase-2 in the prostatic tissues were effectively reduced | [83] |
| Fruit         | Methanolic extract  | Human breast cancer and normal kidney epithelial cell lines | 20–200 µg/mL | Methanolic fruit extract showed substantial anticancer activity by reducing cell viability | [11] |
| Leaves        | Methanol and chloroform extract | Cell cultures include normal and cancerous human prostate cell lines | 10–250 µg/mL | Extract exerted its cancer-preventing action by inducing apoptosis, decreasing cell viability, invasion, cell proliferation, and migration of prostate cancerous cells | [84] |
| Whole plant   | Water and methanol extract | Forty Wistar rats (200–250 g) | 250, 500, and 1000 mg/kg BW | *W. coagulans* extract caused decreased malondialdehyde levels and increased total antioxidant capacity levels in the prostate gland | [85] |
| Fruit         | Ethanol extract     | Human breast cancer cell line | 0, 10, 20, 40, 80, 160 and 320 µg/mL | Plant extract arrested cell cycle at G2/M phase and was found non-hemolytic | [86] |
| Root, leaf, leaf stalk, and fruit | Methanolic extracts | Human and rat cancer cell lines | 20 µg/mL | The leaf stalk extract showed the highest cytotoxic activity against all tested cell lines | [87] |
| Leaf          | Silver nanoparticles(leaf extract) | Cervical cancerous hyper-triploid cell-lines | 0.25–30 mg/L | Silver nanoparticles containing withanolides unveiled cytotoxic and apoptotic potential | [69] |

**Anticancer Activity**

**Other Health Benefits**

| Part of Plant | Type of Intervention | Experimental Model | Dosage | Outcomes | References |
|---------------|---------------------|--------------------|--------|----------|------------|
| Whole plant   | Hydroalcoholic extract | Male Wistar rats (48) | 250, 500, and 1000 mg/kg BW/day | Results showed a significant decrease in sperm count, gonadosomatic index, and sperm viability | [85] |
| Whole plant   | Ethanolic extracts | Vermicidal activity against *Phereetina posthuma* earthworm | 75 and 100 mg/mL | *W. coagulans* extract exhibited remarkable anti-helminthic activity against *P. posthuma* | [17] |
| Fruit         | Alcoholic extract   | Swiss Albino mice | 200, 500, and 1000 mg/kg BW | Fruit extract was evaluated as an antidepressant as it reduced the immobility and increased the mobility in rats through tail suspension test | [88] |
| Root          | Ethanol water (3:1) extract | Male Wistar rats | 500 and 1000 mg/kg BW | Neuro-protective potential against oxidative stress-induced injury was illustrated with enhancement in the number of intact neurons and suppression in the number of TUNEL neurons in the hippocampal region | [89] |
| Roots         | Methanol and water (3:1) extract | Male Wistar rats (220–250 g) | 1000 mg/kg BW | Preischemic extract administration effectively increased the antioxidant status (catalase, glutathione peroxidase, and superoxide dismutase level) and reduced the malondialdehyde level in the striatum brain region. | [90] |
### Table 3. Cont.

| Part of Plant | Type of Intervention | Experimental Model | Dosage | Outcomes | References |
|---------------|----------------------|--------------------|--------|----------|------------|
| Roots         | Methanol and water (3:1) | Male Wistar rats (220–250 g) | 1000 mg/kg BW | Preischemic extract administration effectively increased the antioxidant status (catalase, glutathione peroxidase, and superoxide dismutase level) and reduced the malondialdehyde level in the striatum brain region. | [90] |
| Whole plant   | Methanol and chloroform (1:1) | Sprague-Dawley rats (180–220 g) | 200, 100, and 50 mg/kg BW | The antinociceptive potential of W. coagulans estimated via hot plate assay elucidated pain reduction by 65.3% and 62% by writhing assay | [74] |
| Fruits        | Methanolic extract | Mice | 100 and 250 mg/kg BW | Study results suggested analgesic and sedative activity of W. coagulans | [91] |
| Fruit         | Alcoholic extract | Swiss Albino mice | 200 mg/kg, 500 mg/kg, and 1000 mg/kg | The alcoholic extract did not exhibit an antidepressant effect in rats, but it showed a depressive effect on mood | [92] |
| Fruit         | Alcoholic extract | Swiss Albino mice | 200, 500 and 1000 mg/kg BW | Results showed no considerable association between W. coagulans fruit extract and catalepsy | [93] |
| Fruit         | Alcoholic extract | Swiss Albino mice | 200, and 1000 mg/kg BW | Rota road test also exhibited central nervous system depressant activity | [88] |
| Fruit         | Hydroalcoholic extract (50% ethanol) | Male one-day-old broiler chickens (600) | 0, 100, or 200 mg/kg diet | Non-significant impact on the mineralization of tibia bone was illustrated. Dietary calcium level was declined by 30% and total antibodies level was not influenced significantly | [94,95] |
| Fruit         | Hydroalcoholic extract | Male one-day-old broiler chickens (550) | 150 and 75 mg/kg diet | W. coagulans and W. somnifera administration increased the bone mineralization | [96] |

### 8. Conclusions

*W. coagulans* possesses considerable therapeutic potential and has been employed as a remedy against various disorders and diseases due to the presence of withanolides. It also possesses esterases, free amino acids, fatty oils, and essential oils. Medicinal properties of *W. coagulans* such as hepatoprotective, anti-inflammatory, hypoglycaemic, cardioprotective, free radical scavenging, antimicrobial, central nervous system depressant, immunomodulation, antitumor, and cytotoxic activities have been revealed by several pharmacological studies. However, future studies are needed to explore the mechanisms of action of compounds isolated from *W. coagulans* in higher animals to confirm their protective activity and safety. Crude extracts from different parts of the plant especially from the fruit have significant medicinal potential. Modern medications can be developed after thorough research into the mechanism of action, bioactivity, toxicity, and pharmacotherapeutic potential of plant-derived beneficial chemicals, as well as clinical trials and standardization.

**Author Contributions:** All authors contributed equally for original drafting, editing and finalizing of the review paper. Conceptualization, M.I.K. and M.M.; draft preparation, M.I.K., M.M. and R.A.S.; tables and figures preparation, M.M., M.K., A.A., A.S. and H.S.M.; writing—review and editing, M.K., A.M. and R.M.A.; supervision, M.I.K. and R.M.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.
References

1. Pandey, I.; Nama, K.S. Withania coagulans (Stocks) Dunal A rare ethnomedicinal plant of the Western Rajasthan Desert. Int. J. Pharmaceut. Biomed. Res. 2015, 2, 34–40.

2. Negi, M.; Sabharwal, V.; Wilson, N.; Lakshmikumaran, M. Comparative analysis of the efficiency of SAMPL and AFLP in assessing genetic relationships among Withania somnifera genotypes. Curr. Sci. 2006, 91, 464–471.

3. Gupta, V.; Keshari, B.B. Withania coagulans Dunal (peanne doda): A review. Int. J. Ayurvedic Herb. Med. 2013, 3, 1130–1136.

4. Ullah, Z.; Baloch, M.K.; Khader, J.A.; Baloch, I.B.; Ullah, R.; AbdElslam, N.M.; Noor, S. Proximate and nutrient analysis of selected medicinal plants of Tank and South Waziristan area of Pakistan. Afr. J. Pharm. Pharmacol. 2013, 7, 179–184. [CrossRef]

5. Ram, H.; Kumar, P.; Purohit, A.; Kashyap, P.; Kumar, S.; Kumar, S.; Singh, G.; Alqarawi, A.A.; Hashem, A.; Abd_Allah, E.F. Improvements in HOMA indices and pancreatic endocrinial tissues in type-2 diabetic rats by DPP-4 inhibition and antioxidant potential of an ethanol fruit extract of Withania coagulans. Nutr. Metab. 2021, 18, 1–17. [CrossRef] [PubMed]

6. Qasim, S.; Zafar, A.; Saif, M.S.; Ali, Z.; Nazar, M.; Waqas, M.; Haq, A.U.; Tariq, T.; Hassan, S.G.; Iqbal, F. Green synthesis of iron oxide nanorods using Withania coagulans extract improved photocatalytic degradation and antimicrobial activity. J. Photochem. Photobiol. B Biol. 2020, 204, 111784. [CrossRef]

7. Peerzade, N.; Sayed, N.; Das, N. Antimicrobial and phytochemical screening of methanolic fruit extract of Withania coagulans L. Dunal for evaluating the antidiabetic activity. Pharma Innov. J. 2018, 7, 197–204.

8. Qureshi, S.A.; Jahan, M.; Lateef, T.; Ahmed, D.; Rais, S.; Azmi, M.B. Presence of gallic acid and rutin improve the hepatoprotective strength of Withania coagulans. Pak. J. Pharm. Sci. 2019, 32, 301–308.

9. Lateef, T.; Qureshi, S.A. Centratherum anheimliticum and Withania coagulans improves lipid profile and oxidative stress in triton X-100 induced hyperlipidemic rabbits. Group 2020, 1, 1–22.

10. Keshari, A.K.; Srivastava, A.; Upadhyayaya, M.; Srivastava, R. Antioxidants and free radicals scavenging activity of medicinal Plants. J. Pharmacogn. Phytochem. 2018, 7, 1499–1504.

11. Ahmad, R.; Fatima, A.; Srivastava, A.; Khan, M.A. Evaluation of apoptotic activity of Withania coagulans methanolic extract against human breast cancer and vero cell lines. J. Ayurveda Integr. Med. 2017, 8, 177–183. [CrossRef] [PubMed]

12. Gosavi, D.D.; Kamdi, A.S.; Kalameb, S.M.; Bohra, P.N. The motor coordination activity of alcoholic extract of Withania coagulans fruits in Swiss albino mice by rata rod test. Indian J. Pharm. Pharmacol. 2020, 7, 73–76.

13. Mirakzehi, M.; Hosseini, S.; Saleh, H. The effects of hydroalcoholic extracts of Withania somnifera root, Withania coagulans fruit and 1, 2-dihydroxycholecalciferol on immune response and small intestinal morphology of broiler chickens. J. Appl. Anim. Res. 2017, 45, 591–597. [CrossRef]

14. Reddy, S.S.; Chauhan, P.; Maurya, P.; Saini, D.; Yadav, P.P.; Barthwal, M.K. Coagulin-L ameliorates TLR4 induced oxidative damage and immune response by regulating mitochondria and NOX-derived ROS. Toxical. Appl. Pharmacol. 2016, 309, 87–100. [CrossRef] [PubMed]

15. Maurya, R.; Jayendra, A. Chemistry and pharmacology of Withania coagulans: An Ayurvedic remedy. J. Pharm. Pharmacol. 2010, 62, 153–160. [CrossRef]

16. Mudassir, H.A.; Nazim, K.; Khan, U.A.; Qureshi, S.A. Comparative evaluation of hypoglycemic activity, trace minerals and phytochemical contents of some potential medicinal plant extracts. Int. J. Biol. Biotechnol. 2018, 15, 55–62.

17. Saratha, R.; KAS, M.S.; Sundari, K.K. Evaluation of anti-helminthic activity of ethanolic extract of Withania somnifera. J. Med. Plants Res. 2010, 4, 5388–5399.

18. Hameed, I.; Hussain, F. Proximate and elemental analysis of five selected medicinal plants of family Solanaceae. Pak. J. Pharm. Sci. 2015, 28, 1203–1215.

19. Ali, A.; Jameel, M.; Ali, M. New fatty acid, aromatic ester and monoterpenic benzyl glucoside from the fruits of Withania coagulans Dunal. Nat. Prod. Res. 2015, 29, 1307–1314. [CrossRef]

20. Shahnaz, B.; Tahira, M.; Ismat, N. Chemical composition of the essential oil of Withania coagulans. Asian J. Chem. 2010, 22, 122–126.

21. Vishnoi, H.; Garg, A.K.; Meena, G.C.; Singh, C.; Sharma, L.N. Pharmacognostical and pharmacological evaluation of Withania coagulans—an important ethnomedicinal plant. World J. Pharm. Med. Res. 2017, 3, 106–111.

22. Salam, A.; Wahid, M. Free sugars and a galactoaraban from Withania coagulans seeds. Pak. J. Biochem. 1969, 2, 18–21.

23. Atal, C.; Sethi, P. A preliminary chemical examination of Withania coagulans. Indian J. Pharm. Sci. 1963, 25, 163–164.

24. Abbas, S.; Jamal, S.A.; Choudhary, M.I. New withanolides from Withania sp. J. Nat. Prod. 1993, 56, 1000–1006.

25. Kapoor, L. Handbook of Ayurvedic Medicinal Plants: Herbal Reference Library, 1st ed.; CRC Press: Boca Raton, FL, USA, 2000; Volume 2.

26. Jain, R.; Kachhwaha, S.; Kothari, S. Phytochemistry, pharmacology, and biotechnology of Withania somnifera and Withania coagulans: A review. J. Med. Plants Res. 2012, 6, 5388–5399.

27. Mir, S.R.; Ali, M.; Waris, M.; Sultana, S. Medicinal plant constituents from the fruits of Withania coagulans (Stocks) Dunal. Trends Phytochem. Res. 2020, 4, 45–58.

28. Prasad, S.; Singh, P.; Wahi, A.; Hemalatha, S. Pharmacognostical standardization of Withania coagulans Dunal. Pharmacogn. J. 2010, 2, 386–394. [CrossRef]
29. Valizadeh, M.; Bagheri, A.; Valizadeh, J.; Mirjalili, M.; Moshtaghi, N. Phytochemical investigation of Withania coagulans (Stocks) Dunal in natural habits of Sistan and Baluchestan province of Iran. *Iran. J. Med. Aromat. Plants* 2015, 31, 406–417.

30. Azhar, M.F.; Naseer, U.; Aziz, A.; Zafar, S.; Qadir, I.; Farooq, M.; Ahmad, I.; Anjum, K. Antioxidant and phytochemical composition of leaves, stem and root extracts of Withania coagulans and Withania somnifera. *Zeitschrift Arznei-Gewurzpflanzen* 2020, 25, 27–30.

31. Glotter, E. Withanolides and related ergostane-type steroids. *Nat. Prod. Rep.* 1991, 8, 415–440. [CrossRef] [PubMed]

32. Alfonso, D.; Bernardinelli, G.; Kapetanidis, I. Withanolides from Iochroma coccineum. *Phytochemistry* 1993, 34, 517–521. [CrossRef]

33. Tursunova, R.; Maslennikova, V.; Abubakirov, N. Withanolides in the vegetable kingdom. *Chem. Nat. Compd.* 1977, 13, 131–138. [CrossRef]

34. Khodaei, M.; Jafari, M.; Noori, M. Remedial use of withanolides from Withania coagulans (Stocks) Dunal. *Adv. Life Sci.* 2012, 2, 6–19. [CrossRef]

35. Subramanian, S.S.; Sethi, P. Withaferin-A from the roots of Withania coagulans. *Curr. Sci.* 1969, 38, 267–268.

36. Subramanian, S.S.; Sethi, P.; Glotter, E.; Kirson, I.; Lavie, D. 5, 20α-(R)-dihydroxy-6α, 7α-epoxy-1-oxo-5α witha-2, 24-dienolide, a new steroidal lactone from Withania coagulans. *Phytochemistry* 1997, 10, 685–688. [CrossRef]

37. Budhiraja, R.; Sudhir, S.; Garg, K. Cardiovascular effects of a withanolide from Withania coagulans, Dunal fruits. *Indian J. Physiol. Pharmacol.* 1983, 27, 129–134. [PubMed]

38. Velde, V.V.; Lavie, D.; Budhiraja, R.D.; Sudhir, S.; Garg, K.N. Potential biogenetic precursors of withanolides from Withania coagulans. *Phytochemistry* 1983, 22, 2253–2257. [CrossRef]

39. Neogi, P.; Kawai, M.; Butsugan, Y.; Mori, Y.; Suzuki, M. Withacoagin, a new withanolide from Withania coagulans roots. *Bull. Chem. Soc. Jpn.* 1988, 61, 4479–4481. [CrossRef]

40. Choudhary, M.I.; Parveen, Z.; Jabbar, A.; Ali, I. Antifungal steroidal lactones from Withania coagulance. *Phytochemistry* 1995, 40, 1243–1246. [CrossRef]

41. Atta-ur-Rahman, A.; Choudhary, M.I.; Qureshi, S.; Gul, W.; Yousaf, M. Two new steroidal lactones from Withania coagulans. *J. Nat. Prod.* 1998, 61, 812–814. [CrossRef] [PubMed]

42. Shabbir, M.; Yousaf, M.; Qureshi, S.; Naz, A.; Choudhary, M.I. Three withanolides from Withania coagulans. *Phytochemistry* 1999, 52, 1361–1364.

43. Naz, A.; Choudhary, M.I. Withanolides from Withania coagulans. *Phytochemistry* 2003, 63, 387–390.

44. Nur-e-Alam, M.; Yousaf, M.; Qureshi, S.; Baig, I.; Nasim, S.; Choudhary, M.I. A novel dimeric podophyllotoxin-type lignan and a new withanolide from Withania coagulans. *Heterocycl. Chem. Acta* 2003, 86, 607–614. [CrossRef]

45. Mirjalali, M.H.; Moyano, E.; Bonfill, M.; Cusido, R.M.; Palazón, J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. *Molecules* 2009, 14, 2373–2393. [CrossRef] [PubMed]

46. Xu, Y.-M.; Gao, S.; Bunting, D.P.; Gunatilaka, A.L. Unusual withanolides from aerobiologically grown Withania somnifera. *Phytochemistry* 2011, 72, 518–522. [CrossRef]

47. Shahwar, D.E. *Isolation and Structural Studies on the Withanolidal Constituents of Withania coagulans*; University of Karachi: Karachi, Pakistan, 1999.

48. Rahman, A.; Choudhary, M.I. New natural products from medicinal plants of Pakistan. *Pure Appl. Chem.* 1998, 70, 385–389. [CrossRef]

49. Nawaz, H.R.; Malik, A.; Khan, P.M.; Ahmed, S. Ajugin E and F: Two withanolides from Ajuga parviflora. *Phytochemistry* 1999, 52, 1357–1360. [CrossRef]

50. Naz, A. *Studies on the Chemical Constituents of Withania coagulans and Boswellia dalsizii*; University of Karachi: Karachi, Pakistan, 1999.

51. Maurya, R.; Singh, A.B.; Srivastava, A.K. Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity. *Bioorganic Med. Chem. Lett.* 2008, 18, 6534–6537. [CrossRef]

52. Jahan, E.; Perveen, S.; Fatima, I.; Malik, A. Coagulansins A and B, new withanolides from Withania coagulans Dunal. *Heterocycl. Acta* 2010, 93, 530–535. [CrossRef]

53. Khan, S.A.; Adhikari, A.; Ayub, K.; Farooq, A.; Mahar, S.; Qureshi, M.N.; Rauf, A.; Khan, S.B.; Ludwig, R.; Mahmood, T. Isolation, characterization and DFT studies of epoxy ring containing new withanolides from Withania coagulans Dunal. *Spectrochem. Acta Part A Mol. Biomol. Spectrosc.* 2019, 217, 113–121. [CrossRef] [PubMed]

54. Khan, S.A.; Maher, S.; Naheed, N.; Mahmood, T.; Ayub, K.; Farooq, A.; Khan, S.B.; Shah, Z. Isolation, spectroscopic and density functional theory of two withanolide glycosides. *J. Mol. Struct.* 2019, 1177, 449–456. [CrossRef]

55. Maher, S.; Choudhary, M.I.; Saleem, F.; Rasheed, S.; Waheed, I.; Halim, S.A.; Azeem, M.; Abdullah, I.B.; Froyen, M.; Mirza, M.U. Isolation of anti diabetics withanolide from Withania coagulans Dunal and their in vitro and in silico validation. *Biology* 2020, 9, 197. [CrossRef]

56. Huang, C.F.; Ma, L.; Sun, L.J.; Ali, M.; Arfan, M.; Liu, J.W.; Hu, L.H. Immunosuppressive withanolides from Withania coagulans. *Chem. Biodivers.* 2009, 6, 1415–1426. [CrossRef] [PubMed]

57. Kuroyanagi, M.; Murata, M.; Nakane, T.; Shirota, O.; Sekita, S.; Fuchino, H.; Shinwari, Z.K. Leishmanicidal active withanolides from a Pakistani medicinal plant. *Coagulans Chem. Pharm. Bull.* 2012, 60, 892–897. [CrossRef]

58. Ramaiah, P.A.; Lavie, D.; Budhiraja, R.D.; Sudhir, S.; Garg, K.N. Spectroscopic studies on a withanolide from Withania coagulans. *Phytochemistry* 1984, 23, 143–149. [CrossRef]
59. Beigomi, M.; Mohammadifar, M.A.; Hashemi, M.; Senthil, K.; Valizadeh, M. Biochemical and rheological characterization of a protease from fruits of Withania coagulans with a milk-clotting activity. Food Sci. Biotechnol. 2014, 23, 1805–1813. [CrossRef]

60. Kazemipour, N.; Salehi Inchebron, M.; Valizadeh, J.; Sephrimanesht, M. Clotting characteristics of milk by Withania coagulans: Proteomic and biochemical study. Int. J. Food Prop. 2017, 20, 1290–1301. [CrossRef]

61. Salehi, M.; Aghamaali, M.R.; Sajedi, R.H.; Asghari, S.M.; Jorjani, E. Purification and characterization of a milk-clotting aspartic protease from Withania coagulans fruit. Int. J. Biol. Macromol. 2017, 98, 847–854. [CrossRef] [PubMed]

62. Pezeshki, A.; Hessari, J.; AHDAMI, Z.A.; Ghambazadeh, B. Influence of Withania coagulans protease as a vegetable rennet on proteolysis of Iranian UF white cheese. J. Agric. Sci. Technol. 2011, 13, 567–576.

63. Nawaz, M.A.; Masud, T.; Sammi, S. Quality evaluation of mozzarella cheese made from buffalo milk by using paneer booti (Withania coagulans) and calf rennet. Int. J. Dairy Technol. 2011, 64, 218–226. [CrossRef]

64. Qazalbash, M.A.; Masud, T.; Sammi, S.; Khan, R.S.; Latif, A. Effect of different storage conditions on coagulating properties and cheese quality of Withania coagulans extract. Int. J. Dairy Technol. 2018, 71, 654–662. [CrossRef]

65. Jooyandeh, H.; Ghasemi, A.; Hojjati, M.; Nasehi, B. Utilization of Withania coagulans extract as a rennet replacer on color and physicochemical characteristics of ultrafiltered Iranian white cheese. Iran. J. Food Sci. Technol. 2020, 17, 1–13.

66. Khan, R.S.; Masud, T. Comparison of buffalo cottage cheese made from aqueous extract of Withania coagulans with commercial calf rennet. Int. J. Dairy Technol. 2013, 66, 396–401. [CrossRef] [PubMed]

67. Sarani, R.; Mohtadinia, J.; Asghari, J.M. The use of the Withania coagulans as a coagulant in the production of soya cheese and the effect of various additives on the sensory properties. J. Food Res. 2015, 25, 627–687.

68. Atrarod, M.; Nasrollahzadeh, M.; Sajadi, S.M. Green synthesis of Pd/RGO/FeSO4 nanocomposite using Withania coagulans leaf extract and its application as magnetically separable and reusable catalyst for the reduction of 4-nitrophenol. J. Colloid Interface Sci. 2016, 465, 249–258. [CrossRef]

69. Tripathi, D.; Modi, A.; Narayan, G.; Rai, S.P. Green and cost effective synthesis of silver nanoparticles from endangered medicinal plant Withania coagulans and their potential biomedical properties. Mater. Sci. Eng. C 2019, 100, 152–164. [CrossRef]

70. Sampaathkumar, K.; Rijayan, S.; Tan, C.K.; Demokritou, P.; Chudapongse, N.; Loo, S.C.J. Small-intestine-specific delivery of antidiabetic extracts from Withania coagulans using polysaccharide-based enteric-coated nanoparticles. ACS Omega 2019, 4, 12049–12057. [CrossRef] [PubMed]

71. Kesahri, A.; Srivastava, R.; Yadav, S.; Nath, G.; Gond, S. Synergistic activity of green silver nanoparticles with antibiotics. Nanomed. Res. J. 2020, 5, 44–54.

72. Quaisul, H. In vivo effect of withacoagul and coagulin C isolated from Withania coagulans Dunal fruits on blood pressure of albino rats. World J. Adv. Res. Rev. 2019, 4, 27–32. [CrossRef]

73. Quaisul, H. In vivo cardioprotective effect of withacoagul (20β,27-Dihydroxy-1-oxo-(22R)-witha-2,5,24-tetraenolide) in experimental myocardial infarction in albino rats. World J. Adv. Res. Rev. 2020, 5, 36–42. [CrossRef]

74. Ismail, H.; Rasheed, A.; Haq, I.U.; Jafari, L.; Ullah, N.; Dilshad, E.; Sajid, M.; Mirza, B. Five indigenous plants of Pakistan with antinoceptive, anti-inflammatory, antidepressant, and anticoagulant properties in Sprague Dawley rats. Evid.-Based Complementary Altern. Med. 2017, 2017, 7849501. [CrossRef]

75. Maher, S.; Shabbir, M.; Anam, I.; Khan, N.; Iqbal, S.; Saleem, F. Anti-inflammatory and anti-oxidant activities of methanolic extract of medicinal plants from Balochistan. Int. J. Biol. Macromol. 2015, 6881, 6881–6891. [CrossRef]

76. Ullah, A.; Khan, A. In vitro antibacterial potential of Withania coagulans Dunal (Solanaceae). J. Biodivers. Environ. Sci. 2018, 12, 139–146.

77. Sharma, S.; Joshi, A.; Hemalatha, S. Protective effect of Withania coagulans fruit extract on cisplatin-induced nephrotoxicity in rats. Pharmacogn. Res. 2017, 9, 354.

78. Sadeghi, M.; Arshadi, A.; Mirdar Harjiani, J.M.H.; Haddadi, F. Antioxidant activity of chitosan edible coating enriched with aqueous extract of Withania coagulans fruit on chemical changes and sensory properties of silver carp (Hypophthalmichthys molitrix) stored in refrigerator. J. Fish. 2020, 72, 363–374.

79. Samad, A.; Sadiq, N.; Ayaz, H.; Rajpoot, N.N. Antidiabetic effect of withanolides and liraglutide on serum insulin level and pancreatic histology in diabetic rats. Prof. Med. J. 2019, 26, 1898–1903. [CrossRef]

80. Samad, A.; Rajpoot, N.N.; Ayaz, H.; Sadiq, N. Effect of Withania coagulans and liraglutide on serum Glp-1, postprandial and fasting blood glucose in streptozotocin induced diabetic rats. J. Bahria Univ. Med. Dent. Coll. 2019, 9, 120.

81. Siriporn, R. Evaluation of Antidiabetic Activity of the Water and Ethyl Acetate Fractions from Withania coagulans Fruits and the Mechanism Underlying Their Hypoglycemic Effects; School of Preclinical Institute of Science Suranaree University of Technology: Nakhon Ratchasima, Thailand, 2018.

82. Sandhiya, V.; Krishna, M.S. Effect of chloroform fraction of Withania coagulans bud on the regulation of GLUT4 and PPAR γ-expressions levels in diabetic L6 myotubes. Int. J. Life-Sci. Sci. Res. 2016, 2, 285–289. [CrossRef]

83. Sarbishegi, M.; Khajavi, O.; Arab, M.R. Withania coagulans extract induces cell apoptosis and inhibits COX-2 expression in a rat model of benign prostatic hyperplasia. Nephro-Urol. Mon. 2016, 8, e39284. [CrossRef]

84. Rehman, S.; Keefover-Ring, K.; ul Haq, I.; Dilshad, E.; Khan, M.J.; Akhtar, N.; Mirza, B. Drier climatic conditions increase withanolide content of Withania coagulans enhancing its inhibitory potential against human prostate cancer cells. Appl. Biochem. Biotechnol. 2019, 188, 460–480. [CrossRef] [PubMed]
85. Sarbishegi, M.; Khajavi, O. Effects of hydro-alcoholic extract of *Withania coagulans* on antioxidant status and sperm parameters following testosterone administration in rat. *J. Ilam Univ. Med. Sci.* 2018, 26, 11–20. [CrossRef]

86. Gopinath, S.; Ismail Shareef, M.; Gupta, S.; Gupta, A. In vitro anticancer evaluation of *Withania coagulans* on breast cancer cell lines. *World J. Pharm. Pharm. Sci.* 2017, 6, 933–940.

87. Maqsood, M.; Qureshi, R.; Ikram, M.; Ahmad, M.S.; Jabeen, B.; Asi, M.R.; Khan, J.A.; Ali, S.; Lilge, L. In vitro anticancer activities of *Withania coagulans* against HeLa, MCF-7, RD, RG2, and INS-1 cancer cells and phytochemical analysis. *Integr. Med. Res.* 2018, 7, 184–191. [CrossRef] [PubMed]

88. Gosavi, D.D.; Kamdi, A.S. The antidepressant activity of alcoholic extract of *Withania coagulans* fruits in Swiss albino mice by tail suspension test. *Natl. J. Physiol. Pharm. Pharmacol.* 2020, 10, 527–529. [CrossRef]

89. Sarbishegi, M.; Heidari, Z.; Mahmoudzadeh-Sagheb, H.; Valizadeh, M.; Doostkami, M. Neuroprotective effects of *Withania coagulans* root extract on CA1 hippocampus following cerebral ischemia in rats. *Avicenna J. Phytomed.* 2016, 6, 399. [PubMed]

90. Mahmoudzadeh-Sagheb, H.; Heidari, Z.; Sarbishegi, M. *Withania coagulans* protects striatum from oxidative damages induced by global brain ischemia in rat. *Jundishapur J. Nat. Pharm. Prod.* 2018, 13, e65051. [CrossRef]

91. Ahmad, N.; Muhammad, S.; Fatima, K.; Ahmad, R.; Shahwani, N.A.; Jabbar, A. CNS depressant and analgesic effects of *Withania coagulans* (Stocks) Dunal fruits collected from Khuzdar district of Balochistan, Pakistan. *Pure Appl. Biol.* 2017, 6, 636–644. [CrossRef]

92. Kamdi, A.S.; Bohra, P.N.; Kalambe, S.M.; Chandrakapure, A.R. The antidepressant activity of the alcoholic extract of *Withania coagulans* fruits in Swiss albino mice by forced swimming test. *Natl. J. Physiol. Pharm. Pharmacol.* 2019, 9, 904–906. [CrossRef]

93. Kamdi, A.S.; Kokane, S.; Bohra, P.N.; Kalambe, S.M. The antipsychotic activity of alcoholic extract of *Withania coagulans* fruits in Swiss albino mice in haloperidol-induced catalepsy. *Natl. J. Physiol. Pharm. Pharmacol.* 2018, 8, 1654–1656. [CrossRef]

94. Hosseini, S.J.; Kermanshahi, H.; Nassirimoghaddam, H.; Nabipour, A.; Mirakzehi, M.T.; Saleh, H.; Kazemifard, M. Effects of 1,25-dihydroxycholecalciferol and hydroalcoholic extract of *Withania coagulans* fruit on bone mineralization and mechanical and histological properties of male broiler chickens. *Braz. J. Poult. Sci.* 2016, 18, 73–86. [CrossRef]

95. Hosseini, S.J.; Mirakzehi, M.; Saleh, H. The effects of dietary 1, 25-Dihydroxycholecalciferol (Calcitriol) and root hydroalcoholic extract of *Withania coagulans* on immune response and small intestinal morphology of broiler chickens. *Sci.-Res. Iran. Vet. J.* 2016, 12, 27–32.

96. Mirakzehi, M.; Hosseini, S.; Saleh, H. Effects of two plant extracts and vitamin D3 on bone mechanical and histological properties of broiler chickens. *JAPS J. Anim. Plant Sci.* 2018, 28, 686–694.